Scientists discovered a moth that appears 3D despite having flat wings. Tiny structures on its wings reflect light that ...
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at ...
Researchers have been trying to find new ways to produce and replicate the various useful features observed in nature. Fine ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.
HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...
Figure AI, a robotics company working to bring a general-purpose humanoid robot into commercial and residential use, announced Tuesday on X that it is exiting a deal with OpenAI. The Bay Area ...
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals ... reporting on how money influences those businesses and shapes what we all pay for care. He is also the author ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback